Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremie Guedj

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Nature Reviews. Gastroenterology & Hepatology|July 1, 2015
Modelling hepatitis C therapy--predicting effects of treatmentAlan S Perelson, Jeremie Guedj
Hepatology (Baltimore, Md.)|March 9, 2011
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment durationJeremie Guedj, Alan S Perelson
Biometrics|April 10, 2010
Joint modeling of the clinical progression and of the biomarkers' dynamics using a mechanistic modelJeremie Guedj, Rodolphe Thiébaut, Daniel Commenges
BMC Medical Research Methodology|April 27, 2013
Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approachCédric Laouénan, Jeremie Guedj, France Mentré
Liver International : Official Journal of the International Association for the Study of the Liver|November 15, 2014
Can we use viral kinetic models to individualize treatment?Jeremie Guedj, Thi Huyen Tram Nguyen
Acta Obstetricia Et Gynecologica Scandinavica|May 14, 2013
Umbilical artery Doppler assessment: a clear disparity in ultrasound practice in a national surveyJonathan Cohen, Jeremie Guedj, Nicolas Fries
Antiviral Therapy|August 24, 2016
Reply to: Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV - some considerationsLaetitia Canini, Jeremie Guedj, Alan S Perelson
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2011
Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapyJeremie Guedj, Harel Dahari, Alan S Perelson
Hepatology (Baltimore, Md.)|March 25, 2011
Silibinin mode of action against hepatitis C virus: a controversy yet to be resolvedHarel Dahari, Jeremie Guedj, Alan S Perelson
Antiviral Therapy|November 29, 2012
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?Anushree Chatterjee, Jeremie Guedj, Alan S Perelson
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Nature Reviews. Gastroenterology & Hepatology|July 1, 2015
Modelling hepatitis C therapy--predicting effects of treatmentAlan S Perelson, Jeremie Guedj
Hepatology (Baltimore, Md.)|March 9, 2011
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment durationJeremie Guedj, Alan S Perelson
Biometrics|April 10, 2010
Joint modeling of the clinical progression and of the biomarkers' dynamics using a mechanistic modelJeremie Guedj, Rodolphe Thiébaut, Daniel Commenges
BMC Medical Research Methodology|April 27, 2013
Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approachCédric Laouénan, Jeremie Guedj, France Mentré
Liver International : Official Journal of the International Association for the Study of the Liver|November 15, 2014
Can we use viral kinetic models to individualize treatment?Jeremie Guedj, Thi Huyen Tram Nguyen
Acta Obstetricia Et Gynecologica Scandinavica|May 14, 2013
Umbilical artery Doppler assessment: a clear disparity in ultrasound practice in a national surveyJonathan Cohen, Jeremie Guedj, Nicolas Fries
Antiviral Therapy|August 24, 2016
Reply to: Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV - some considerationsLaetitia Canini, Jeremie Guedj, Alan S Perelson
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2011
Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapyJeremie Guedj, Harel Dahari, Alan S Perelson
Hepatology (Baltimore, Md.)|March 25, 2011
Silibinin mode of action against hepatitis C virus: a controversy yet to be resolvedHarel Dahari, Jeremie Guedj, Alan S Perelson
Antiviral Therapy|November 29, 2012
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?Anushree Chatterjee, Jeremie Guedj, Alan S Perelson
Pageof 6